2021
Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS)
Brunner A, Gavralidis A, Al Ali N, Komrokji R, Zeidan A, Sallman D. Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS). Blood 2021, 138: 1522. DOI: 10.1182/blood-2021-151815.Peer-Reviewed Original ResearchClinical Trials CommitteeStable diseaseComplete remissionHMA therapyBone marrow blastsHematologic improvementProgressive diseaseMyelodysplastic syndromePartial remissionTrials CommitteeResponse criteriaMarrow blastsOverall survivalSpeakers bureauHigh-risk myelodysplastic syndromeAdvisory CommitteeIncomplete hematologic recoveryIWG 2006 criteriaMethod of KaplanRisk myelodysplastic syndromesOngoing prospective studyMoffitt Cancer CenterBest overall responsePrediction of OSMassachusetts General Hospital
2013
The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)
Zeidan A, Al Ali N, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette P, Lancet J, List A, Komrokji R. The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza). Blood 2013, 122: 2771. DOI: 10.1182/blood.v122.21.2771.2771.Peer-Reviewed Original ResearchMD Anderson Prognostic Scoring SystemMedian overall survivalHigh-risk groupMoffitt Cancer CenterAZA therapyHR-MDSOverall survivalPrognostic scoring systemMyelodysplastic syndromeIntermediate riskRisk groupsLower riskScoring systemPrognostic groupsInt-2Therapy-related myelodysplastic syndromeHigh-risk myelodysplastic syndromeCycles of therapyHR-MDS patientsKaplan-Meier curvesLog-rank testOff-label useAZA initiationR-IPSSRevised IPSS